Recombinant HRP Anti-c-Myc antibody [Y69] (ab205818)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- HRP Rabbit monoclonal [Y69] to c-Myc
- Suitable for: WB
- Reacts with: Human
- Conjugation: HRP
Related conjugates and formulations
Overview
-
Product name
HRP Anti-c-Myc antibody [Y69]
See all c-Myc primary antibodies -
Description
HRP Rabbit monoclonal [Y69] to c-Myc -
Host species
Rabbit -
Conjugation
HRP -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
(Peptide available asab166837) -
Positive control
- WB: A20 whole cell lysate (ab7180), Raji and K562 whole cell lysates.
-
General notes
If you need other conjugated anti-c-myc (Y69) RabMAb antibodies, find our range of products here.
We also offer a PBS only version of this clone as product ab168727.
For more information on choosing the right c-Myc antibody for you, please visit Antibodies to c-Myc and Myc tag.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. Store In the Dark. -
Storage buffer
pH: 7.40
Preservative: 0.1% Proclin 300 Solution
Constituents: 30% Glycerol (glycerin, glycerine), 1% BSA, PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
Y69 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
- Anti-c-Myc antibody [Y69] - ChIP Grade - BSA and Azide free (ab168727)
- Alexa Fluor® 488 Anti-c-Myc antibody [Y69] (ab190026)
- Alexa Fluor® 647 Anti-c-Myc antibody [Y69] (ab190560)
- Alexa Fluor® 594 Anti-c-Myc antibody [Y69] (ab201775)
- Alexa Fluor® 555 Anti-c-Myc antibody [Y69] (ab201780)
- FITC Anti-c-Myc antibody [Y69] (ab223913)
- Anti-c-Myc antibody [Y69] - ChIP Grade (ab32072)
-
Assay kits
-
Immunizing Peptide (Blocking)
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab205818 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/5000. Detects a band of approximately 58 kDa (predicted molecular weight: 48 kDa).Can be blocked with Human c-Myc peptide (ab166837).
|
Notes |
---|
WB
1/5000. Detects a band of approximately 58 kDa (predicted molecular weight: 48 kDa).Can be blocked with Human c-Myc peptide (ab166837). |
Target
-
Function
Participates in the regulation of gene transcription. Binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Seems to activate the transcription of growth-related genes. -
Involvement in disease
Note=Overexpression of MYC is implicated in the etiology of a variety of hematopoietic tumors.
Note=A chromosomal aberration involving MYC may be a cause of a form of B-cell chronic lymphocytic leukemia. Translocation t(8;12)(q24;q22) with BTG1.
Defects in MYC are a cause of Burkitt lymphoma (BL) [MIM:113970]. A form of undifferentiated malignant lymphoma commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. Note=Chromosomal aberrations involving MYC are usually found in Burkitt lymphoma. Translocations t(8;14), t(8;22) or t(2;8) which juxtapose MYC to one of the heavy or light chain immunoglobulin gene loci. -
Sequence similarities
Contains 1 basic helix-loop-helix (bHLH) domain. -
Post-translational
modificationsPhosphorylated by PRKDC. Phosphorylation at Thr-58 and Ser-62 by GSK3 is required for ubiquitination and degradation by the proteasome.
Ubiquitinated by the SCF(FBXW7) complex when phosphorylated at Thr-58 and Ser-62, leading to its degradation by the proteasome. In the nucleoplasm, ubiquitination is counteracted by USP28, which interacts with isoform 1 of FBXW7 (FBW7alpha), leading to its deubiquitination and preventing degradation. In the nucleolus, however, ubiquitination is not counteracted by USP28, due to the lack of interaction between isoform 4 of FBXW7 (FBW7gamma) and USP28, explaining the selective MYC degradation in the nucleolus. Also polyubiquitinated by the DCX(TRUSS) complex. -
Cellular localization
Nucleus > nucleoplasm. Nucleus > nucleolus. - Information by UniProt
-
Database links
- Entrez Gene: 4609 Human
- Entrez Gene: 17869 Mouse
- Entrez Gene: 24577 Rat
- Omim: 190080 Human
- SwissProt: P01106 Human
- SwissProt: P01108 Mouse
- SwissProt: P09416 Rat
- Unigene: 202453 Human
see all -
Form
c-Myc is also expressed in the cytoplasm. -
Alternative names
- AU016757 antibody
- Avian myelocytomatosis viral oncogene homolog antibody
- bHLHe39 antibody
see all
Images
-
All lanes : HRP Anti-c-Myc antibody [Y69] (ab205818) at 1/5000 dilution
Lane 1 : Raji (Human Burkitt's lymphoma cell line) Whole Cell Lysate
Lane 2 : K562 (Human erythromyeloblastoid leukemia cell line) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 48 kDa
Observed band size: 58 kDa why is the actual band size different from the predicted?
Exposure time: 4 minutesThis blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab205818 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
Datasheets and documents
-
SDS download
-
Datasheet download
References (4)
ab205818 has been referenced in 4 publications.
- Zhan Y et al. Decreased DNA Damage and Improved p53 Specificity of RITA Analogs. Mol Cancer Ther 21:1524-1534 (2022). PubMed: 35877475
- Valiuska S et al. Targeting MYC Regulation with Polypurine Reverse Hoogsteen Oligonucleotides. Int J Mol Sci 24:N/A (2022). PubMed: 36613820
- Kilinc S et al. Oncogene-regulated release of extracellular vesicles. Dev Cell 56:1989-2006.e6 (2021). PubMed: 34118203
- Venkataramanan S et al. DDX3X and DDX3Y are redundant in protein synthesis. RNA 27:1577-1588 (2021). PubMed: 34535544